Literature DB >> 9330984

Diagnostic criteria for the neuropathological assessment of Alzheimer's disease: current status and major issues.

H M Wisniewski1, W Silverman.   

Abstract

A Consensus Conference focusing on Alzheimer's disease (AD) took place in November 1996 to recommend uniform evaluation procedures and diagnostic criteria, co-sponsored by the National Institute on Aging and the Reagan Institute of the Alzheimer's Association. In conjunction with this conference, we reviewed diagnostic practices in current use, together with various neuropathological criteria proposed since 1985. Difficulties were identified in developing "gold standard" criteria for diagnosis and case classification of AD based upon the current state of knowledge. Working criteria for use within research contexts were proposed that acknowledged the realities of scientific limitations by inclusion of a broad and heterogeneous category of "uncertain" cases. (Eventually, methods will be developed for identifying these cases as preclinical AD, dementia due to multiple causes or non-AD, but this is not now possible.) Within applied contexts, the use of CERAD guidelines was supported. Finally, recommendations generated at the Consensus Conference were discussed, emphasizing the rapid pace of recent scientific advancement and the need for ongoing empirical reevaluation and modification of the Group's proposal.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9330984     DOI: 10.1016/s0197-4580(97)00068-7

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  3 in total

1.  Interplay between oxidative damage, protein synthesis, and protein degradation in Alzheimer's disease.

Authors:  Jeffrey N Keller
Journal:  J Biomed Biotechnol       Date:  2006

Review 2.  Artificial Intelligence Models in the Diagnosis of Adult-Onset Dementia Disorders: A Review.

Authors:  Gopi Battineni; Nalini Chintalapudi; Mohammad Amran Hossain; Giuseppe Losco; Ciro Ruocco; Getu Gamo Sagaro; Enea Traini; Giulio Nittari; Francesco Amenta
Journal:  Bioengineering (Basel)       Date:  2022-08-05

3.  Icariin decreases the expression of APP and BACE-1 and reduces the β-amyloid burden in an APP transgenic mouse model of Alzheimer's disease.

Authors:  Lan Zhang; Cong Shen; Jin Chu; Ruyi Zhang; Yali Li; Lin Li
Journal:  Int J Biol Sci       Date:  2014-01-21       Impact factor: 6.580

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.